Skip to main content
. 2015 Sep 24;5(3):102–109. doi: 10.5500/wjt.v5.i3.102

Table 1.

Demographic features

Peak-PRA 0%-30%
Peak-PRA 31%-60%
Peak-PRA > 60%
Steroid No steroid Steroid No steroid Steroid No steroid
(n = 25218) (n = 7399) (n = 3495) (n = 850) (n = 4966) (n = 923)
Donor factors
Age 38 ± 17 39 ± 17b 37 ± 17 38 ± 18 35 ± 15 35 ± 16
Gender (M/F) % 59/41 59/41 60/40 57/43 60/40 66/34b
Death from CVA (%) 42 40a 38 41a 36 35a
ECD kidney (%) 18 20d 15 22d 8 10
DCD kidney (%) 7.7 9.1d 6.1 7.6 6.7 8.1
Recipient factors
Age (yr) 51 ± 13 53 ± 13d 37 ± 17 38 ± 17 47 ± 13 49 ± 13
Gender (M/F) % 66/34 67/33 51/49 51/49 37/63 34/66
African American 30 26d 28 28 33 31
Diabetes 33 36d 29 34b 25 28
Pre-transplant dialysis (%) 91 88d 89 84d 91 91
Dialysis duration (mo) 45 ± 34 44 ± 35a 49 ± 42 47 ± 42 61 ± 51 59 ± 52
Previous transplant (%) 7.3 4.6d 21.8 14.6d 44.2 37.9d
HLA mismatches 3.7 ± 1.8 3. 7 ± 1.9 3.5 ± 2.0 3.1 ± 2.0a 3.1 ± 2.0 3.0 ± 2.0
Transplant- related factors
Cold ischemia (h) 18.1 ± 8.1 18.8 ± 8.0d 18.3 ± 7.9 20.8 ± 10.2d 18.4 ± 8.1 19.3 ± 8.2b
Delayed graft function (%) 24.4 19.5d 22.9 19.6a 26 20.8b

P value is for steroid vs no steroid:

a

P < 0.05,

b

P < 0.01;

d

P < 0.001. CVA: Cerebrovascular accident; DCD: Donation after cardiac death; ECD: Expanded criteria donor; HLA: Human leukocyte antigen; PRA: Panel reactive antibody.